New Biomarkers Associated With the Risk of Premature Delivery.
NCT ID: NCT04067908
Last Updated: 2019-08-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
182 participants
INTERVENTIONAL
2011-06-07
2013-12-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study aims to estimate the prognostic value of new biomarkers (proteomic markers) on the occurrence of preterm birth.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Procalcitonin and Threatened Premature Delivery
NCT01977079
Biomarkers in Obstetrical Complications
NCT03480139
Protein and Ultrasound Indicators of Preterm Birth
NCT01412931
Predicting Late-onset Preeclampsia at 10-14 Weeks of Pregnancy
NCT04075708
A Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor
NCT02787213
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The diagnosis of threat of premature labor at high risk of preterm labor is difficult and clinical and laboratory criteria often remain insufficient. Measurement of the cervix by endovaginal ultrasound lacks sensitivity and specificity. Among the biological criteria, only fibronectin, which has a good negative predictive value, is used in current practice. Despite the use of these two prognostic criteria, only 40% of hospitalized patients will give birth prematurely.
Recent advances in proteomics allow us to study complex proteomes and compare them. Preliminary studies already carried out have revealed families of proteins expressed differently in situations of work or premature delivery. We therefore hypothesize that the study of a woman's vaginal proteome with threat of premature labor may reveal new markers of preterm labor. These markers could help the clinician in its therapeutic management and thus reduce hospitalizations, better target patients requiring tocolytic treatment and optimize the use of corticosteroids. In addition, variations in the proteome may help to understand the physiopathological mechanisms of premature delivery, which are necessary for the development of effective therapeutics.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
woman giving birth prematurely
Proteome: by liquid chromatography coupled with tandem mass spectrometry. Fibronectin: by vaginal sampling. Ultrasound of the cervix. Cytokines: ELISA kit of a panel of several cytokines.
2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling
The samples taken during this study are taken at the same time as those taken in routine during the diagnosis of threat of premature labor. There are added 2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling
The samples taken during this study are taken at the same time as those taken in routine during the diagnosis of threat of premature labor. There are added 2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Term from 22 to 33 and 6 amenorrhea weeks
* Single or twin pregnancy
* Emergency consultant, in participating centers, for a threat of premature labor defined by:
Uterine contractions greater than or equal to 3 in 30 minutes Clinical modification of the cervix Ultrasound collar less than 25 mm
* Free, informed and written consent, dated and signed by the patient and the investigator before any investigation required by the research.
* Patient affiliated to a Social Security scheme.
Exclusion Criteria
* Placenta previa
* Vaginal haemorrhage at the time of sampling
* Uterine malformation
* Strapping, open bite
* History of strapping and or open bite
* Conization
* Fetal malformation
* Associated vasorenal pathology
* Sexual intercourse less than 24h
* Gynecological examination less than 48h
* Vaginal treatment in progress
* Polyhydramnios
* Transfused-transfused syndrome
* Twin Anemia Polycythemia syndrome
* Fetoscopy during pregnancy
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Bordeaux
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dominique DALLAY, Pr
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Bordeaux
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHUBX 2010/19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.